Tag: BioNTech

Investor attention is sharply focused on today's CureVac shareholder meeting, which represents a critical juncture for BioNTech. The assembly will ...

The formal dissolution of one of biotech's most prominent partnerships has rattled investors, with Pfizer's complete exit from its BioNTech ...

A surprising development emerged in mid-November when pharmaceutical giant Pfizer divested 54.7% of its stake in BioNTech, triggering a significant ...

A seismic development has rocked BioNTech's stock valuation following the complete divestment of Pfizer's substantial shareholding. The long-standing pandemic partner ...

The German biotech firm BioNTech finds itself navigating turbulent waters following a significant divestment by its longtime collaborator. In a ...

After a prolonged period of disappointing its shareholders, the pioneering coronavirus vaccine developer is showing signs of a potential resurgence. ...

Investors are rallying behind BioNTech stock despite the company's recent quarterly loss, signaling a potential turnaround for the vaccine developer. ...

Today marks a critical juncture for BioNTech as the German biotech firm unveils its strategic roadmap in New York. Investors ...

BioNTech's equity performance is presenting a conundrum for market participants. The company continues to deliver impressive revenue figures and has ...

BioNTech presents investors with a complex financial picture marked by contradictory signals. The German biotech firm reported a substantial 22% ...